GOBIOLAB is showing strong performance. This is interpreted as being influenced by research results indicating that GLP-1 RA agents, which are popular for their weight loss effects, reduce the risk of obesity-related cancer occurrence more than insulin in patients with type 2 diabetes.
As of 2:01 PM on the 8th, GOBIOLAB is trading at 6,900 KRW, up 6.81% compared to the previous day.
According to industry sources, a study published in the American Medical Association journal JAMA Network Open selected patients prescribed GLP-1 RA without insulin, patients prescribed insulin without GLP-1 RA, patients prescribed GLP-1 RA without metformin, and patients prescribed metformin without GLP-1 RA, and analyzed the results based on the type of prescribed medication.
Among 10 types of cancers including gallbladder cancer, meningioma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, esophageal cancer, endometrial cancer, kidney cancer, and multiple myeloma, the risk of cancer occurrence was lower with GLP-1 RA than with insulin.
Meanwhile, GOBIOLAB is developing metabolic disease treatments using microbiome-derived substances. They are researching new drugs that treat various metabolic diseases such as obesity through GLP-1 induction. This drug is known to act on enteroendocrine cells distributed in the intestines to induce the secretion of GLP-1.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
